134 related articles for article (PubMed ID: 34145572)
1. Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
Testi AM; Mohamed S; Diverio D; Piciocchi A; Menna G; Rizzari C; Timeus F; Micalizzi C; Lo Nigro L; Santoro N; Masetti R; Micheletti MV; Ziino O; Onofrillo D; Ladogana S; Putti C; Pierani P; Arena V; Zecca M; Foà R; Locatelli F
Br J Haematol; 2021 Oct; 195(2):278-283. PubMed ID: 34145572
[No Abstract] [Full Text] [Related]
2. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
4. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
Naina HV; Levitt D; Vusirikala M; Anderson LD; Scaglioni PP; Kirk A; Collins RH
J Clin Oncol; 2011 Jun; 29(18):e534-6. PubMed ID: 21482998
[No Abstract] [Full Text] [Related]
6. Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
Fouzia NA; Sharma V; Ganesan S; Palani HK; Balasundaram N; David S; Kulkarni UP; Korula A; Devasia AJ; Nair SC; Janet NB; Abraham A; Mani T; Lakshmanan J; Balasubramanian P; George B; Mathews V
Br J Haematol; 2021 Jan; 192(2):292-299. PubMed ID: 33216980
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
Gill H; Yim R; Lee HKK; Mak V; Lin SY; Kho B; Yip SF; Lau JSM; Li W; Ip HW; Hwang YY; Chan TSY; Tse E; Au WY; Kumana CR; Kwong YL
Cancer; 2018 Jun; 124(11):2316-2326. PubMed ID: 29579321
[TBL] [Abstract][Full Text] [Related]
8. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
Russell N; Burnett A; Hills R; Betteridge S; Dennis M; Jovanovic J; Dillon R; Grimwade D;
Blood; 2018 Sep; 132(13):1452-1454. PubMed ID: 30097508
[No Abstract] [Full Text] [Related]
9. Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
Fujita H; Asou N; Iwanaga M; Hyo R; Nomura S; Kiyoi H; Okada M; Inaguma Y; Matsuda M; Yamauchi T; Ohtake S; Izumi T; Nakaseko C; Ishigatsubo Y; Shinagawa K; Takeshita A; Miyazaki Y; Ohnishi K; Miyawaki S; Naoe T;
Cancer Sci; 2013 Oct; 104(10):1339-45. PubMed ID: 23837667
[TBL] [Abstract][Full Text] [Related]
10. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
Garcia Spezza E; Brethon B; Petit A; Mazingue F; Gandemer V; Boissel N; Carausu L; Reguerre Y; Leverger G; Ducassou S
Br J Haematol; 2020 Jan; 188(1):170-173. PubMed ID: 31808943
[No Abstract] [Full Text] [Related]
11. [Successful treatment of acute promyelocytic leukaemia without chemotherapy and blood transfusion].
Tøstesen M; Østgård LSG; Kjeldsen E; Stentoft J; Nørgaard JM
Ugeskr Laeger; 2018 Jan; 180(3):. PubMed ID: 29336300
[TBL] [Abstract][Full Text] [Related]
12. Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review.
Rhee JY; Tremblay D; Chan AM; Tallman MS; Mascarenhas J
Blood Adv; 2019 Jun; 3(12):1854-1857. PubMed ID: 31213431
[TBL] [Abstract][Full Text] [Related]
13. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
14. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
15. [Acute promyelocytic leukaemia].
Tøstesen M; Østergård LSG; Kjeldsen E; Stentoft J; Nørgaard JM
Ugeskr Laeger; 2018 Jan; 180(3):. PubMed ID: 29336301
[TBL] [Abstract][Full Text] [Related]
16. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
18. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.
Gill HS; Yim R; Kumana CR; Tse E; Kwong YL
Cancer; 2020 Jul; 126(14):3244-3254. PubMed ID: 32365228
[TBL] [Abstract][Full Text] [Related]
19. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
[TBL] [Abstract][Full Text] [Related]
20. Towards Optimizing Risk-adapted Treatment of APML in ATRA/ATO Era: How Can Prediction of Early Mortality Help?
Buhtoiarov IN
J Pediatr Hematol Oncol; 2021 May; 43(4):158. PubMed ID: 33625082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
